176 related articles for article (PubMed ID: 8358734)
41. c-myc gene abnormalities in mucosa-associated lymphoid tissue (MALT) lymphomas.
Peng H; Diss T; Isaacson PG; Pan L
J Pathol; 1997 Apr; 181(4):381-6. PubMed ID: 9196434
[TBL] [Abstract][Full Text] [Related]
42. Mutation of the p53 gene in postradiation sarcoma.
Nakanishi H; Tomita Y; Myoui A; Yoshikawa H; Sakai K; Kato Y; Ochi T; Aozasa K
Lab Invest; 1998 Jun; 78(6):727-33. PubMed ID: 9645763
[TBL] [Abstract][Full Text] [Related]
43. [Competitive polymerase chain reaction: a new method for measuring N-myc amplification].
Tornóczky T; Vass J; Kajtár P; Kardos M; Lendvai G; Varga T; Pajor L
Orv Hetil; 2000 Jan; 141(1):27-30. PubMed ID: 10673855
[TBL] [Abstract][Full Text] [Related]
44. Discordant p53 gene mutations in primary head and neck cancers and corresponding second primary cancers of the upper aerodigestive tract.
Chung KY; Mukhopadhyay T; Kim J; Casson A; Ro JY; Goepfert H; Hong WK; Roth JA
Cancer Res; 1993 Apr; 53(7):1676-83. PubMed ID: 8453641
[TBL] [Abstract][Full Text] [Related]
45. Clustered mutations in the second exon of the MYC gene in sporadic Burkitt's lymphoma.
Yano T; Sander CA; Clark HM; Dolezal MV; Jaffe ES; Raffeld M
Oncogene; 1993 Oct; 8(10):2741-8. PubMed ID: 8397370
[TBL] [Abstract][Full Text] [Related]
46. Mutations in exon 7 and 8 of p53 as poor prognostic factors in patients with non-small cell lung cancer.
Huang C; Taki T; Adachi M; Konishi T; Higashiyama M; Miyake M
Oncogene; 1998 May; 16(19):2469-77. PubMed ID: 9627113
[TBL] [Abstract][Full Text] [Related]
47. Heterogeneous gene alterations in primary breast cancer contribute to discordance between primary and asynchronous metastatic/recurrent sites: HER2 gene amplification and p53 mutation.
Sekido Y; Umemura S; Takekoshi S; Suzuki Y; Tokuda Y; Tajima T; Osamura RY
Int J Oncol; 2003 Jun; 22(6):1225-32. PubMed ID: 12738987
[TBL] [Abstract][Full Text] [Related]
48. [The status of p53 gene in the primary retinoblastoma].
Huang Q
Zhonghua Yan Ke Za Zhi; 1999 Jul; 35(4):248-51. PubMed ID: 11835813
[TBL] [Abstract][Full Text] [Related]
49. Infrequent p53 mutation in mouse tumors with deregulated myc.
Gutierrez MI; Bhatia K; Siwarski D; Wolff L; Magrath IT; Mushinski JF; Huppi K
Cancer Res; 1992 Feb; 52(4):1032-5. PubMed ID: 1737333
[TBL] [Abstract][Full Text] [Related]
50. Molecular genetics of malignant insulinoma.
Pavelic K; Hrascan R; Kapitanovic S; Vranes Z; Cabrijan T; Spaventi S; Korsic M; Krizanac S; Li YQ; Stambrook P; Gluckman JL; Pavelic ZP
Anticancer Res; 1996; 16(4A):1707-17. PubMed ID: 8712689
[TBL] [Abstract][Full Text] [Related]
51. p53 null mutations undetected by immunohistochemical staining predict a poor outcome with early-stage non-small cell lung carcinomas.
Hashimoto T; Tokuchi Y; Hayashi M; Kobayashi Y; Nishida K; Hayashi S; Ishikawa Y; Tsuchiya S; Nakagawa K; Hayashi J; Tsuchiya E
Cancer Res; 1999 Nov; 59(21):5572-7. PubMed ID: 10554037
[TBL] [Abstract][Full Text] [Related]
52. [N-myc status of neuroblastoma from bone marrow cells].
Brack T; Finckenstein FG; Kabisch H
Klin Padiatr; 1991; 203(4):323-7. PubMed ID: 1942939
[TBL] [Abstract][Full Text] [Related]
53. Preferential amplification of the paternal allele of the N-myc gene in human neuroblastomas.
Cheng JM; Hiemstra JL; Schneider SS; Naumova A; Cheung NK; Cohn SL; Diller L; Sapienza C; Brodeur GM
Nat Genet; 1993 Jun; 4(2):191-4. PubMed ID: 8102299
[TBL] [Abstract][Full Text] [Related]
54. Duplication of N-MYC at its resident site 2p24 may be a mechanism of activation alternative to amplification in human neuroblastoma cells.
Corvi R; Savelyeva L; Schwab M
Cancer Res; 1995 Aug; 55(16):3471-4. PubMed ID: 7627947
[TBL] [Abstract][Full Text] [Related]
55. High-resolution mapping of the N-myc amplicon core domain in neuroblastomas.
Hiemstra JL; Schneider SS; Brodeur GM
Prog Clin Biol Res; 1994; 385():51-7. PubMed ID: 7972237
[TBL] [Abstract][Full Text] [Related]
56. Structural features of the amplified N-myc oncogene detected by micrococcal nuclease digestion of neuroblastoma cell nuclei.
Telford DJ; Stewart BW
Biochem Int; 1990 Sep; 21(6):1025-32. PubMed ID: 2080918
[TBL] [Abstract][Full Text] [Related]
57. Consistent N-myc copy number in simultaneous or consecutive neuroblastoma samples from sixty individual patients.
Brodeur GM; Hayes FA; Green AA; Casper JT; Wasson J; Wallach S; Seeger RC
Cancer Res; 1987 Aug; 47(16):4248-53. PubMed ID: 2440561
[TBL] [Abstract][Full Text] [Related]
58. Low frequency of the p53 gene mutations in neuroblastoma.
Hosoi G; Hara J; Okamura T; Osugi Y; Ishihara S; Fukuzawa M; Okada A; Okada S; Tawa A
Cancer; 1994 Jun; 73(12):3087-93. PubMed ID: 8200007
[TBL] [Abstract][Full Text] [Related]
59. Amplification and rearrangement of DNA sequences from the chromosomal region 2p24 in human neuroblastomas.
Shiloh Y; Korf B; Kohl NE; Sakai K; Brodeur GM; Harris P; Kanda N; Seeger RC; Alt F; Latt SA
Cancer Res; 1986 Oct; 46(10):5297-301. PubMed ID: 3756879
[TBL] [Abstract][Full Text] [Related]
60. Prognostic prediction in neuroblastomas: clinical significance of combined analysis for Ha-ras p21 expression and N-myc gene amplification.
Tanaka T; Seeger RC; Tanabe M; Hiyama E; Shimoda H; Ida N
Cancer Detect Prev; 1994; 18(4):283-9. PubMed ID: 7982238
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
